Market Overview

PROLOR to Issues Preclinical Trial Results from Studies of Long-Acting Clotting Factor VIIa-CTP, Sees Two Factor VIIA-CTP Programs Beginning 2014

Related PBTH
OPKO Completes Acquisition Of PROLOR Biotech
PROLOR Biotech Commences Phase III Trial of Longer-Acting Version of HGH
Related OPK
Sears, Walgreen And Others Insiders Have Been Buying
American Eagle Outfitters, Continental Resources, Inc. And Other Insiders Have Been Buying
Opko Health Replaces CFO (Fox Business)

PROLOR Biotech, Inc. (NYSE: PBTH), today announced that the company will present new results from preclinical studies of its long-acting clotting factor VIIa (Factor VIIa-CTP), a next-generation investigational therapy in advanced preclinical development for the potential treatment of hemophilia. The data provide further evidence that Factor VIIa-CTP has the potential to be administered by subcutaneous (SC) injection as well as intravenously (IV), which would facilitate its prophylactic use by patients on an ongoing basis. The study results will be discussed in an oral presentation at the XXIV Congress of the International Society of Hemostasis and Thrombosis (ISTH).

Currently available commercial factor VIIa must be administered through IV infusion, which can be onerous for patients. This limits its use for prophylactic treatment and can require frequent administrations if patients are treated only "on demand" when a bleeding episode occurs. 

The new preclinical results being presented at the ISTH Congress further confirm the efficacy of PROLOR's long-acting Factor VIIa-CTP and show that it has the potential to be administered using a simple SC injection. The combination of a long-acting product coupled with the ability to be administered by SC injection could change the way that factor VIIa is used, potentially allowing individuals with hemophilia to self-administer the drug at home on a prophylactic basis, improving their quality of life and potentially reducing the need for on-demand treatment of bleeding episodes.

Posted-In: News FDA

 

Related Articles (PBTH)

Around the Web, We're Loving...

Get Benzinga's Newsletters